Related Experiment Video
Updated: Jan 26, 2026

Single Liposome Measurements for the Study of Proton-Pumping Membrane Enzymes Using Electrochemistry and Fluorescent Microscopy
Published on: February 21, 2019
Outcome of stroke patients on clopidogrel plus proton-pump inhibitors: a single-center cohort study
Insights
Co-prescribing clopidogrel with proton pump inhibitors (PPI) did not increase mortality risk in stroke patients. This combination was associated with lower 30-day unplanned readmission rates.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Recent studies indicate a potential increased risk of adverse cardiovascular events and mortality when clopidogrel is co-prescribed with proton pump inhibitors (PPIs).
- This raises concerns regarding the safety of this common drug combination, particularly in vulnerable patient populations.
Purpose of the Study:
- To investigate the impact of concomitant clopidogrel and PPI use on 30-day unplanned hospital readmissions and one-year all-cause mortality.
- To compare outcomes between patients receiving clopidogrel with PPIs, clopidogrel with H2 blockers, and clopidogrel without gastric acid suppressants.
Main Methods:
- A retrospective longitudinal cohort study was conducted at a single academic tertiary center.
- Data from 464 patients admitted with stroke between 2010 and 2014 were analyzed.
- Outcomes, including one-year mortality and 30-day unplanned readmissions, were compared using multivariable logistic regression.
Main Results:
- Among 175 patients discharged on clopidogrel, 107 received PPIs and 36 received H2 blockers.
- Clopidogrel plus PPI use was not associated with increased one-year mortality (6.2% vs. 4.8% in non-PPI cohort; OR 0.6, P=0.6).
- The clopidogrel plus PPI group showed a significantly lower risk of 30-day unplanned readmission (OR 0.6, P=0.03).
Conclusions:
- Concomitant use of clopidogrel and PPIs in stroke patients was not linked to higher mortality rates.
- This drug combination was associated with reduced 30-day unplanned readmission rates.
- Limitations include the single-center nature and retrospective design, precluding generalizability and analysis of treatment duration or compliance.
Background:
Recent studies suggest a higher risk of adverse cardiovascular outcome and mortality in patients co-prescribed clopidogrel with proton pump inhibitors (PPI).
Objective:
Investigate the impact of concomitant prescription of clopidogrel and PPI on 30-day unplanned readmission and one-year all-cause mortality.
Design:
Retrospective longitudinal cohort study.
Setting:
Single academic tertiary center.
Patients And Methods:
The study included patients admitted with a diagnosis of ischemic or hemorrhagic stroke between 2010 and 2014. Demographic and outcome data were collected and compared for patients on clopidogrel plus PPI vs those on clopidogrel plus H2blockers and those not on clopidogrel.
Main Outcome Measures:
One-year mortality and 30-day unplanned readmissions were compared among different patient groups using multivariable logistic regression modeling.
Sample Size:
464 patients.
Results:
Out of 464 patients, 175 (37.7%) were discharged on clopidogrel. The concomitant prescription of clopidogrel and PPI was noted in 107 (24.4%) and clopidogrel and H2 blockers in 36 patients (7.8%). The one-year all-cause mortality in the entire cohort was 22.2%. Patients on clopidogrel plus PPI did not have a higher risk of one-year mortality compared to the non-PPI cohort (6.2% vs. 4.8%, p 0.7). There was a non-significant suggestion of lower one-year mortality in patients on clopidogrel plus PPI vs those not on clopidogrel (6.2% vs. 10.1%, p 0.23). In multivariable logistic regression, the use of clopidogrel plus PPI did not predict higher one-year mortality (odds ratio 0.6, P=0.6). The risk of unplanned 30-day readmission was lower in those with clop-idogrel plus PPI (odds ratio 0.6, P=.03).
Conclusion:
The use of clopidogrel plus PPI resulted in lower readmission rates and was not associated with higher mortality compared with the non-PPI cohorts.
Limitations:
Single center study, not generalizable. Given the retrospective nature of this study, we did not collect data on duration of treatments or patient compliance.
Conflict Of Interest:
None.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Patient-centered Care
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
ATP Driven Pumps III: V-type Pumps
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
ATP Driven Pumps II: P-type Pumps
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...

